PURPOSE: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system mediated by T cells. B7-H3 plays a diverse role in regulating T cell responses. However, its expression and clinical significance in MS are not well known. This study analyzed the expression of membrane B7-H3 (mB7-H3) and levels of soluble B7-H3 (sB7-H3) in MS patients to determine its clinical significance. METHODS: Peripheral blood (PB) or cerebrospinal fluid (CSF) samples from healthy controls, other noninflammatory neurological disorders, viral encephalitis, and MS patients were collected. Expression of mB7-H3 on immune cells was detected by flow cytometry. Levels of sB7-H3 in serum or CSF samples were measured by ELISA. RESULTS: mB7-H3 expression was up-regulated in CSF from MS patients compared to PB (p<0.001). However, serum or CSF levels of sB7-H3 in MS patients were significantly lower than those in controls (p<0.05). Relapsing-MS patients had higher CSF mB7-H3 expression than the remitting subgroup. Relapsing-MS patients had decreased serum and CSF sB7-H3 levels compared with the remitting subgroup. Neurological deficits showed negative correlations with serum or CSF sB7-H3 levels, but a positive correlation with CSF mB7-H3 expression. Methylprednisolone therapy significantly elevated sB7-H3 levels and reduced mB7-H3 expression compared with pre-therapy levels. sB7-H3 levels did not correlate with mB7-H3 expression. CONCLUSIONS: We demonstrated enhanced mB7-H3 expression and reduced sB7-H3 levels in MS patients which correlated with the clinical characteristics of MS patients. These results suggest that B7-H3 may be a promising biomarker and associated with the pathogenesis of MS.
PURPOSE:Multiple sclerosis (MS) is an autoimmune disease of the central nervous system mediated by T cells. B7-H3 plays a diverse role in regulating T cell responses. However, its expression and clinical significance in MS are not well known. This study analyzed the expression of membrane B7-H3 (mB7-H3) and levels of soluble B7-H3 (sB7-H3) in MSpatients to determine its clinical significance. METHODS: Peripheral blood (PB) or cerebrospinal fluid (CSF) samples from healthy controls, other noninflammatory neurological disorders, viral encephalitis, and MSpatients were collected. Expression of mB7-H3 on immune cells was detected by flow cytometry. Levels of sB7-H3 in serum or CSF samples were measured by ELISA. RESULTS:mB7-H3 expression was up-regulated in CSF from MSpatients compared to PB (p<0.001). However, serum or CSF levels of sB7-H3 in MSpatients were significantly lower than those in controls (p<0.05). Relapsing-MSpatients had higher CSF mB7-H3 expression than the remitting subgroup. Relapsing-MSpatients had decreased serum and CSF sB7-H3 levels compared with the remitting subgroup. Neurological deficits showed negative correlations with serum or CSF sB7-H3 levels, but a positive correlation with CSF mB7-H3 expression. Methylprednisolone therapy significantly elevated sB7-H3 levels and reduced mB7-H3 expression compared with pre-therapy levels. sB7-H3 levels did not correlate with mB7-H3 expression. CONCLUSIONS: We demonstrated enhanced mB7-H3 expression and reduced sB7-H3 levels in MSpatients which correlated with the clinical characteristics of MSpatients. These results suggest that B7-H3 may be a promising biomarker and associated with the pathogenesis of MS.
Authors: Roberta Castriconi; Alessandra Dondero; Raffaella Augugliaro; Claudia Cantoni; Barbara Carnemolla; Angela Rita Sementa; Francesca Negri; Romana Conte; Maria Valeria Corrias; Lorenzo Moretta; Alessandro Moretta; Cristina Bottino Journal: Proc Natl Acad Sci U S A Date: 2004-08-16 Impact factor: 11.205
Authors: W-K Suh; S X Wang; A H Jheon; L Moreno; S K Yoshinaga; B Ganss; J Sodek; M D Grynpas; T W Mak Journal: Proc Natl Acad Sci U S A Date: 2004-08-18 Impact factor: 11.205
Authors: S K Yoshinaga; J S Whoriskey; S D Khare; U Sarmiento; J Guo; T Horan; G Shih; M Zhang; M A Coccia; T Kohno; A Tafuri-Bladt; D Brankow; P Campbell; D Chang; L Chiu; T Dai; G Duncan; G S Elliott; A Hui; S M McCabe; S Scully; A Shahinian; C L Shaklee; G Van; T W Mak; G Senaldi Journal: Nature Date: 1999-12-16 Impact factor: 49.962
Authors: Chinh N Tran; Seth G Thacker; Deanna M Louie; Jennifer Oliver; Peter T White; Judith L Endres; Andrew G Urquhart; Kevin C Chung; David A Fox Journal: J Immunol Date: 2008-03-01 Impact factor: 5.422
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422